Header Logo

Connection

Kathleen Moore to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Ovarian Neoplasms.
Kathleen Moore
Connection Strength
15.071
Ovarian Neoplasms
  1. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. Int J Gynecol Cancer. 2024 Nov; 34(11):1753-1760.
    View in: PubMed
    Score: 0.601
  2. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Dec; 191:249-258.
    View in: PubMed
    Score: 0.592
  3. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.
    View in: PubMed
    Score: 0.546
  4. Homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022 03; 33(3):231-233.
    View in: PubMed
    Score: 0.488
  5. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022 01 01; 28(1):36-44.
    View in: PubMed
    Score: 0.480
  6. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480.
    View in: PubMed
    Score: 0.479
  7. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388.
    View in: PubMed
    Score: 0.461
  8. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 06; 32(6):757-765.
    View in: PubMed
    Score: 0.460
  9. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
    View in: PubMed
    Score: 0.459
  10. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497.
    View in: PubMed
    Score: 0.446
  11. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
    View in: PubMed
    Score: 0.444
  12. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 09 15; 26(18):4767-4776.
    View in: PubMed
    Score: 0.439
  13. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639.
    View in: PubMed
    Score: 0.437
  14. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
    View in: PubMed
    Score: 0.437
  15. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 05; 157(2):379-385.
    View in: PubMed
    Score: 0.428
  16. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
    View in: PubMed
    Score: 0.420
  17. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301.
    View in: PubMed
    Score: 0.407
  18. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
    View in: PubMed
    Score: 0.403
  19. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505.
    View in: PubMed
    Score: 0.390
  20. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018 11; 151(2):190-195.
    View in: PubMed
    Score: 0.389
  21. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.
    View in: PubMed
    Score: 0.385
  22. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703.
    View in: PubMed
    Score: 0.375
  23. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
    View in: PubMed
    Score: 0.372
  24. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503.
    View in: PubMed
    Score: 0.370
  25. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401.
    View in: PubMed
    Score: 0.362
  26. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36.
    View in: PubMed
    Score: 0.345
  27. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63.
    View in: PubMed
    Score: 0.331
  28. PARP inhibition in ovarian cancer: state of the science. Gynecol Oncol. 2015 Jan; 136(1):8-10.
    View in: PubMed
    Score: 0.300
  29. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80.
    View in: PubMed
    Score: 0.201
  30. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9.
    View in: PubMed
    Score: 0.190
  31. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403.
    View in: PubMed
    Score: 0.183
  32. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024 07; 186:61-68.
    View in: PubMed
    Score: 0.143
  33. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
    View in: PubMed
    Score: 0.135
  34. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023 03; 170:241-247.
    View in: PubMed
    Score: 0.131
  35. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022 08; 23(8):e374-e384.
    View in: PubMed
    Score: 0.127
  36. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
    View in: PubMed
    Score: 0.123
  37. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423.
    View in: PubMed
    Score: 0.120
  38. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49.
    View in: PubMed
    Score: 0.118
  39. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882.
    View in: PubMed
    Score: 0.106
  40. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019 10; 155(1):69-74.
    View in: PubMed
    Score: 0.103
  41. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. Phys Med Biol. 2018 08 06; 63(15):155020.
    View in: PubMed
    Score: 0.096
  42. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.094
  43. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
    View in: PubMed
    Score: 0.090
  44. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290.
    View in: PubMed
    Score: 0.090
  45. Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017 09; 146(3):465-469.
    View in: PubMed
    Score: 0.089
  46. Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women. Gynecol Oncol. 2017 08; 146(2):268-272.
    View in: PubMed
    Score: 0.089
  47. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 10; 24(10):1233-1239.
    View in: PubMed
    Score: 0.089
  48. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.088
  49. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145.
    View in: PubMed
    Score: 0.088
  50. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):236-242.
    View in: PubMed
    Score: 0.087
  51. Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52.
    View in: PubMed
    Score: 0.084
  52. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
    View in: PubMed
    Score: 0.083
  53. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4.
    View in: PubMed
    Score: 0.080
  54. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol. 2016 Sep; 57(9):1149-55.
    View in: PubMed
    Score: 0.080
  55. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9.
    View in: PubMed
    Score: 0.080
  56. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005 May; 192(5):1614-9.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.